BOULDER, Colo., July 28, 2014 Array BioPharma Inc. (Nasdaq: ARRY) will report financial results for the fourth quarter and full year of fiscal 2014 and hold a conference call to discuss those results on Tuesday, August 12, 2014. Ron Squarer, Chief Executive Officer and Michael Carruthers, Chief Financial Officer will lead the call.

http://photos.prnewswire.com/prnvar/20121029/LA02195LOGO 



    Conference Call Information

    Date:                                         Tuesday, August 12, 2014

    Time:                                         9:00 a.m. Eastern Time

    Toll-Free:                                    (800) 708-4540

    Toll:                                         (847) 619-6397

    Pass Code:                                                              37609587

    Webcast, including Replay and Conference Call Slides:

    http://investor.arraybiopharma.com/phoenix.zhtml?c=123810&p=irol-irhome

About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Seven Phase 3 studies are in progress, or are planned to begin this year. These programs include the wholly-owned hematology drug, filanesib (ARRY-520) for multiple myeloma and two partnered cancer drugs, selumetinib (AstraZeneca) and binimetinib (MEK162 / Novartis). For more information on Array, please go to www.arraybiopharma.com. 



    CONTACT:                        Tricia Haugeto

                                    Array BioPharma Inc.

                                    (303) 386-1193

                                    thaugeto@arraybiopharma.com

Logo - http://photos.prnewswire.com/prnh/20121029/LA02195LOGO

SOURCE Array BioPharma Inc.